Last reviewed · How we verify
NCT04219215
Acute Hyperbaric Oxygen Treatment Increases Hepatic Insulin Sensitivity and Muscle Reactive Oxygen Species in T2D
NA trial testing 100% O2 in oxygen chamber in Type 2-diabetes in 12 participants. Completed in 20 September 2022.
20 September 2022
Quick facts
| Lead sponsor | German Diabetes Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 February 2020 |
| Primary completion | 20 September 2022 |
| Estimated completion | 20 September 2022 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- 100% O2 in oxygen chamber
- 21% O2 in oxygen chamber
Conditions studied
- Type 2-diabetes — all drugs for Type 2-diabetes →
Sponsor
German Diabetes Center — full company profile →
Who can join
Adults 18 to 75, male only, with Type 2-diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Diabetes mellitus type 2 (T2D) is characterized by insulin resistance of liver and skeletal muscle, which is at least partly due to impaired muscle mitochondrial function. Long-term HBO therapy, as applied for treating the diabetic foot syndrome, has been shown to improve blood glucose concentrations. To study the underlying mechanisms, we want to examin the short-term effect of HBO treatment on insulin sensitivity and mitochondrial oxidative capacity and production of reactive oxygen species (ROS) in a randomized, double blinded, placebo-controlled cross-over trial.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial.
Sarabhai T, Mastrototaro L, Kahl S, Bönhof GJ, et al · · 2023 · cited 14× · PMID 36178534 · DOI 10.1007/s00125-022-05797-0
Verify or expand the search:
- PubMed search for NCT04219215
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other German Diabetes Center trials
Trials by the same sponsor.
- NCT06193668 — Overfeeding Induced Fat-tissue Stimulation · NA · recruiting
- NCT04222231 — RESIST! Blood-flow Restriction Resistance Training for Improving Insulin Sensitivity in Type 2 Diabetes · NA · unknown
- NCT04088851 — "Hepatic Substrate Flux Rates in Type 2 Diabetes" · NA · active not recruiting
- NCT05046483 — Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI · recruiting
- NCT04509245 — The Effects of a Novel Lifestyle Intervention Program on Insulin Sensitivity in Type 2 Diabetes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04219215 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by German Diabetes Center
- Last refreshed: 15 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04219215.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing